En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
PCRD EU
Numéro de projet
02.0155-1
Titre du projet
HEPCVAX: Unraveling HCV pathogenicity for the preclinical development of new therapeutic strategies
Titre du projet anglais
HEPCVAX: Unraveling HCV pathogenicity for the preclinical development of new therapeutic strategies

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Mots-clé
-
-
-
Anzeigen
Autre Numéro de projet
-
-
-
Anzeigen
Programme de recherche
-
-
-
Anzeigen
Description succincte
-
-
-
Anzeigen
Autres indications
-
-
-
Anzeigen
Résumé des résultats (Abstract)
-
-
-
Anzeigen
Références bases de données
-
-
-
Anzeigen

Textes saisis


CatégorieTexte
Mots-clé
(Anglais)
Life Sciences; Medicine; Health; Safety; Scientific Research; Social Aspects
Autre Numéro de projet
(Anglais)
EU project number: QLK2-CT-2002-01329
Programme de recherche
(Anglais)
EU-programme: 5. Frame Research Programme - 1.1.2 Control of infectious diseases
Description succincte
(Anglais)
See abstract
Autres indications
(Anglais)
Full name of research-institution/enterprise:
Universität Bern
Institut für klinische Pharmakologie
Résumé des résultats (Abstract)
(Anglais)
The overall objectives of the HepCVax cluster is to identify viral and host mechanisms which are involved in:
i) viral replication and particle formation;
ii) pathogenicity and viral persistence and, based on the knowledge of virus properties as well as virus-host interactions and pathogenesis;
iii) to identify innovative antiviral and immuno-therapeutic strategies capable of inducing a broad and sustained HCV specific cellular-mediated immune responses. All information emerging from the understanding of the HCV genome will be integrated in the first ever-European sequence database dedicated to Hepatitis C virus. The cluster will be subdivided in three component Networks. Whereas HepCVax-PARTIC will concentration the molecular and intracellular level of the virus-host interactions through the identification of factors involved in HCV-particles formation, HepCVax. IMPA TH will focus on the interaction between HCV and different arms of the innate and adaptive immune response. HepCVax-PRECLIN will exploit the expected discoveries made by Networks 1and 2 to develop and test new immuno-therapeutic strategies in vitro and in small animal models.
Références bases de données
(Anglais)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 02.0155-1